FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Bladder Cancer news from FierceBiotech

News

ALSO NOTED: Seattle Genetics to raise cash; Biocancell IIb trial approved;and much more...

> Seattle Genetics plans to raise cash by selling 10 million shares of its stock. Report > Read more...

ALSO NOTED: FDA says no to Indevus; Nektar gets sweetened deal with Baxter; Akela pulls public offering; and much more...

> Indevus Pharmaceuticals says that the FDA has turned thumbs down on its new therapy for bladder cancer, a move that trimmed its stock value. Valstar was pulled from the market five years ago Read more...

ALSO NOTED: BMS hands back drug rights; OncoMethylome in deal with GSK; Celgene shares take a bounce; and much more...

> Bristol-Myers Squibb has returned the rights to vinflunine to Pierre Fabre. The therapy was studied as a treatment for bladder cancer. Read more...

ALSO NOTED: Halozyme inks tech pact; Bioniche gains SPA; Ariad shares on rise; and much more...

> Halozyme Therapeutics has agreed to put its technology to work to develop a new formulation of Baxter's Gammagard Liquid for subcutaneous delivery. Gammagard is used to treat primary Read more...

Press Releases

PRESS RELEASE: Indevus Receives Approvable Letter From FDA for Valstar for Bladder Cancer Therapy

Indevus Receives Approvable Letter From FDA for Valstar for Bladder Cancer Therapy LEXINGTON, Mass., Aug. 17 -- Indevus Pharmaceuticals, Inc. today announced that it has received an approvable letter Read more...